BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 21316823)

  • 1. Current practice and future directions for optimization of platelet transfusions in patients with severe therapy-induced cytopenia.
    Apelseth TO; Hervig T; Bruserud O
    Blood Rev; 2011 May; 25(3):113-22. PubMed ID: 21316823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet transfusion prophylaxis for patients with haematological malignancies: where to now?
    Stanworth SJ; Hyde C; Brunskill S; Murphy MF
    Br J Haematol; 2005 Dec; 131(5):588-95. PubMed ID: 16351634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New strategies for the optimal use of platelet transfusions.
    Blajchman MA; Slichter SJ; Heddle NM; Murphy MF
    Hematology Am Soc Hematol Educ Program; 2008; ():198-204. PubMed ID: 19074082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Background, rationale, and design of a clinical trial to assess the effects of platelet dose on bleeding risk in thrombocytopenic patients.
    Slichter SJ
    J Clin Apher; 2006 Apr; 21(1):78-84. PubMed ID: 16619231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet transfusions for patients with haematological malignancies: who needs them?
    Estcourt LJ; Stanworth SJ; Murphy MF
    Br J Haematol; 2011 Aug; 154(4):425-40. PubMed ID: 21615375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The platelet-refractory bone marrow transplant patient: prophylaxis and treatment of bleeding.
    Benson K; Fields K; Hiemenz J; Zorsky P; Ballester O; Perkins J; Elfenbein G
    Semin Oncol; 1993 Oct; 20(5 Suppl 6):102-9. PubMed ID: 8211211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conservative management of chemotherapeutic-induced thrombocytopenia in women with gynecologic cancers.
    Fanning J; Hilgers RD; Murray KP; Bolt K; Aughenbaugh DM
    Gynecol Oncol; 1995 Nov; 59(2):191-3. PubMed ID: 7590471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic platelet transfusions: should they be a treatment of the past?
    Zeller MP; Al-Habsi KS; Heddle NM
    Curr Opin Hematol; 2014 Nov; 21(6):521-7. PubMed ID: 25203535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.
    Rebulla P; Finazzi G; Marangoni F; Avvisati G; Gugliotta L; Tognoni G; Barbui T; Mandelli F; Sirchia G
    N Engl J Med; 1997 Dec; 337(26):1870-5. PubMed ID: 9407153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study.
    Vadhan-Raj S; Kavanagh JJ; Freedman RS; Folloder J; Currie LM; Bueso-Ramos C; Verschraegen CF; Narvios AB; Connor J; Hoots WK; Broemeling LD; Lichtiger B
    Lancet; 2002 Jun; 359(9324):2145-52. PubMed ID: 12090979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing platelet transfusion therapy.
    Heal JM; Blumberg N
    Blood Rev; 2004 Sep; 18(3):149-65. PubMed ID: 15183900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation.
    Wandt H; Schaefer-Eckart K; Frank M; Birkmann J; Wilhelm M
    Bone Marrow Transplant; 2006 Feb; 37(4):387-92. PubMed ID: 16400342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombocytopenia and platelet transfusions in patients with cancer.
    Valent J; Schiffer CA
    Cancer Treat Res; 2011; 157():251-65. PubMed ID: 21052961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of leukocyte and platelet administration in cancer therapy.
    Walker EM; Cannon A; Mitchum EN
    Ann Clin Lab Sci; 1983; 13(6):453-73. PubMed ID: 6197928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet transfusion. Current techniques, remaining problems, and future prospects.
    Herman JH; Kamel HT
    Am J Pediatr Hematol Oncol; 1987; 9(3):272-86. PubMed ID: 3314551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Transfusion-refractory thrombocytopenia during chemotherapy: pathogenesis, frequency and treatment].
    Helleberg C; Taaning EB; Johnsen HE
    Ugeskr Laeger; 1995 Sep; 157(37):5082-6. PubMed ID: 7502374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
    Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F
    Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vincristine-laden platelet transfusion for patients with refractory thrombocytopenia.
    Ganti AK; Landmark JD; Kessinger A; Smith LM; Tarantolo SR
    In Vivo; 2006; 20(4):559-63. PubMed ID: 16900790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of platelet transfusion triggers in a tertiary-care hospital.
    Cameron B; Rock G; Olberg B; Neurath D
    Transfusion; 2007 Feb; 47(2):206-11. PubMed ID: 17302765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet transfusion therapy.
    Slichter SJ
    Hematol Oncol Clin North Am; 2007 Aug; 21(4):697-729, vii. PubMed ID: 17666286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.